PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 17474500-5 2007 In ALLHAT, the comparison of a thiazide diuretic, an ACE-inhibitor and a calcium antagonist showed that the incidence of new cases of diabetes was the highest in the diuretic group and the lowest in the ACE-inhibitor group. Calcium 73-80 angiotensin I converting enzyme Homo sapiens 203-206 28102744-4 2005 Indeed, in the Syst-EUR study a 42% reduction in strokes was achieved in the calcium antagonist arm when compared to the placebo arm.It is hypothesised that antihypertensive agents that stimulate the AT2-receptor (thiazide diuretics, dihydropyridine calcium antagonists and angiotensin receptor blockers) are more cerebroprotective than drug classes that do not stimulate the AT2-receptor (beta-blockers and ACE inhibitors).The angiotensin receptor blockers are the only drug class that have a dual mechanism of action that could be helpful in preventing strokes in that they not only inhibit the AT1-receptor but also allow stimulation of the AT2-receptor. Calcium 77-84 angiotensin I converting enzyme Homo sapiens 408-411 17204161-16 2007 Dietary calcium intake interacted with the ACE I/D and AT1R A/C polymorphisms to further modulate postexercise hypotension. Calcium 8-15 angiotensin I converting enzyme Homo sapiens 43-46 17011715-5 2007 Statins and angiotensin-converting enzyme inhibitors have been shown to slow calcium accumulation in aortic valves. Calcium 77-84 angiotensin I converting enzyme Homo sapiens 12-41 16518351-7 2006 Relative to thiazide diuretic use, the adjusted rate ratio of end-stage renal failure associated with the use of ACE inhibitors was 2.5 (95% confidence interval 1.3-4.7), whereas it was 0.8 (95% confidence interval 0.5-1.4) for beta-blockers and 0.7 (95% confidence interval 0.4-1.3) for calcium antagonists. Calcium 288-295 angiotensin I converting enzyme Homo sapiens 113-116 16373953-7 2005 This augmented effect of dairy products versus supplemental calcium has been localized, in part, to the whey fraction of dairy and is likely due to additional bioactive compounds, such as angiotensin converting enzyme (ACE) inhibitors in dairy, as well as the rich concentration of branched chain amino acids, which act synergistically with calcium to attenuate adiposity; however, these compounds do not fully account for the observed effects, as whey has significantly greater bioactivity than found in these compounds. Calcium 60-67 angiotensin I converting enzyme Homo sapiens 188-217 16373953-7 2005 This augmented effect of dairy products versus supplemental calcium has been localized, in part, to the whey fraction of dairy and is likely due to additional bioactive compounds, such as angiotensin converting enzyme (ACE) inhibitors in dairy, as well as the rich concentration of branched chain amino acids, which act synergistically with calcium to attenuate adiposity; however, these compounds do not fully account for the observed effects, as whey has significantly greater bioactivity than found in these compounds. Calcium 60-67 angiotensin I converting enzyme Homo sapiens 219-222 15526242-6 2004 Bradykinin is thought to contribute to the cardioprotective effect of ACE inhibition through modification of nitric oxide release, calcium handling and collagen accumulation. Calcium 131-138 angiotensin I converting enzyme Homo sapiens 70-73 12489793-5 2002 ACE inhibitors, when activating the B1 receptor, elevate intracellular calcium [Ca2+]i and release NO from cultured cells. Calcium 71-78 angiotensin I converting enzyme Homo sapiens 0-3 15032651-1 2004 Several intervention studies have shown that some hypolipidemic and hypotensive drugs such as fibrates, 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, angiotensin converting enzyme (ACE) inhibitors and calcium (Ca)-antagonists prevent atherosclerosis. Calcium 225-232 angiotensin I converting enzyme Homo sapiens 174-203 12610747-1 2003 OBJECTIVE: The objective of this study was to assess whether calcium antagonists, which have been proven to dilate the afferent glomerular arteriole, might prevent increases in serum creatinine levels among older subjects who started treatment with angiotensin-converting enzyme (ACE) inhibitors. Calcium 61-68 angiotensin I converting enzyme Homo sapiens 249-278 12610747-1 2003 OBJECTIVE: The objective of this study was to assess whether calcium antagonists, which have been proven to dilate the afferent glomerular arteriole, might prevent increases in serum creatinine levels among older subjects who started treatment with angiotensin-converting enzyme (ACE) inhibitors. Calcium 61-68 angiotensin I converting enzyme Homo sapiens 280-283 12610747-5 2003 RESULTS: Among patients receiving ACE inhibitors, serum creatinine levels increased in 22% of participants who were dispensed calcium antagonists, and in 31% of other patients (P=0.005). Calcium 126-133 angiotensin I converting enzyme Homo sapiens 34-37 12610747-10 2003 Our results indicate that among elderly patients receiving ACE inhibitors, the use of calcium antagonists is associated with a reduced risk of worsening renal function. Calcium 86-93 angiotensin I converting enzyme Homo sapiens 59-62 12610747-11 2003 Thus, these results warrant trials aiming at establishing whether combined treatment with calcium antagonists might allow the use of ACE inhibitors in clinical practice to be expanded to the elderly population. Calcium 90-97 angiotensin I converting enzyme Homo sapiens 133-136 15488653-0 2004 Concurrent treatment with an ACE inhibitor may amplify the utility of calcium supplementation for control of hypertension. Calcium 70-77 angiotensin I converting enzyme Homo sapiens 29-32 15488653-6 2004 Analogous logic suggests that calcium supplementation may be more beneficial for hypertensives in the context of ACE inhibition or blockade of angiotensin II receptors; this supposition that can readily be tested clinically. Calcium 30-37 angiotensin I converting enzyme Homo sapiens 113-116 12799093-10 2003 CONCLUSIONS: The ACE inhibitors have a beneficial effect on BMD and calcium metabolism alterations in hypertensive subjects. Calcium 68-75 angiotensin I converting enzyme Homo sapiens 17-20 12775305-11 2003 When ACE inhibitors and calcium antagonists are compared with the Bayesian method, the outcome is a 14% difference in favor of the ACE inhibitors to prevent coronary disease, with a credibility interval almost reaching identity. Calcium 24-31 angiotensin I converting enzyme Homo sapiens 131-134 12775305-15 2003 CONCLUSION: There is statistically an indisputable difference between ACE inhibitors and calcium antagonists in respect of effects on coronary disease and heart failure when treating hypertensive individuals, ACE inhibitors being more efficacious. Calcium 89-96 angiotensin I converting enzyme Homo sapiens 209-212 12652116-4 2002 Anti-hypertensive therapies such as diuretics, ACE inhibitors and calcium antagonists have been effective in reducing cardiovascular events in type 2 diabetes, though calcium antagonists may be less effective than older therapies and ACE-inhibitors in reducing the risk of heart attacks and heart failure (but possibly more effective in stroke reduction). Calcium 66-73 angiotensin I converting enzyme Homo sapiens 234-237 12420192-7 2002 Calcium antagonist use was more common in patients with angina (27.2% vs 5.1%; P<0.0001), but not nitrates (P=0.8695), diuretics (P=0.4218), digoxin (P=0.2565), beta-blockers (P=0.0820), or ACE inhibitors (P=0.7256). Calcium 0-7 angiotensin I converting enzyme Homo sapiens 193-196 11999543-8 2002 Notably, dairy sources of calcium exert a significantly greater anti-obesity effect than supplemental sources in each of these studies, possibly due to the effects of other bioactive compounds, such as the angiotensin converting enzyme inhibitor found in milk, on adipocyte metabolism, indicating an important role for dairy products in the control of obesity. Calcium 26-33 angiotensin I converting enzyme Homo sapiens 206-235 12222627-6 2002 Data from several clinical trials, including RENAAL, suggest that calcium antagonists may be added to ACE inhibitor or AT1 receptor antagonist therapy as needed to achieve target blood pressure. Calcium 66-73 angiotensin I converting enzyme Homo sapiens 102-105 11815428-11 2002 This effect, which was independent of blood pressure reduction, may account for the improved clinical outcomes achieved with ACE inhibitors compared with calcium antagonists. Calcium 154-161 angiotensin I converting enzyme Homo sapiens 125-128 10099077-8 1998 Calcium antagonists are effective for treating hypertensive patients with chronic renal impairment, and the initial results for calcium antagonists and for combination calcium antagonist-ACE inhibitor therapy have been encouraging. Calcium 0-7 angiotensin I converting enzyme Homo sapiens 187-190 11090788-7 2000 Thus, combination therapy with a calcium antagonist and an ACE inhibitor provides blood pressure control equal to that of high-dose calcium antagonist monotherapy but with significantly fewer dose-dependent adverse experiences such as vasodilatory edema. Calcium 132-139 angiotensin I converting enzyme Homo sapiens 59-62 10757223-12 2000 On the basis of available evidence, it appears that angiotensin-converting enzyme inhibitors, together with a low-dose cardioselective beta-blocker and a diuretic, should be used in most hypertensive type 2 diabetes patients, with calcium antagonists serving as reserve drugs in case of insufficient blood pressure control. Calcium 231-238 angiotensin I converting enzyme Homo sapiens 52-81 9799051-5 1998 The rationale for an ACE inhibitor-calcium antagonist combination is based on the fact that both drugs reduce vasoconstriction through different mechanisms. Calcium 35-42 angiotensin I converting enzyme Homo sapiens 21-24 9799051-6 1998 The ACE inhibitor largely attenuates vasoconstriction through augmentation of vasodilatory kinins and reduction of the vasoconstrictive effect of angiotensin II, whereas the calcium antagonists, through attenuating the transmembrane flux of calcium, inhibit calcium-mediated electromechanical coupling in contractile tissue in response to numerous stimuli. Calcium 241-248 angiotensin I converting enzyme Homo sapiens 4-7 9799051-6 1998 The ACE inhibitor largely attenuates vasoconstriction through augmentation of vasodilatory kinins and reduction of the vasoconstrictive effect of angiotensin II, whereas the calcium antagonists, through attenuating the transmembrane flux of calcium, inhibit calcium-mediated electromechanical coupling in contractile tissue in response to numerous stimuli. Calcium 241-248 angiotensin I converting enzyme Homo sapiens 4-7 9799051-10 1998 There is evidence in clinical trials that ACE inhibitors may offset one of the major side effects associated with calcium antagonist therapy: pedal edema. Calcium 114-121 angiotensin I converting enzyme Homo sapiens 42-45 9799051-12 1998 There is also evidence of reduced calcium antagonist-associated constipation and headache with this type of drug combination, likely because lower doses of this agent are used in combination with ACE inhibitors. Calcium 34-41 angiotensin I converting enzyme Homo sapiens 196-199 10077416-9 1999 The initial results for calcium antagonists and for combination calcium antagonist-ACE inhibitor therapy have been promising. Calcium 64-71 angiotensin I converting enzyme Homo sapiens 83-86 9822144-2 1998 These 2 studies, the Fosinopril versus Amlodipine Cardiovascular Events Randomized Trial (FACET) and Appropriate Blood Pressure Control in Diabetes (ABCD), showed that angiotensin-converting enzyme (ACE) inhibitors may be preferable to calcium antagonists for managing hypertension in diabetic patients; they do not, however, show any harm attributable to calcium antagonists. Calcium 236-243 angiotensin I converting enzyme Homo sapiens 168-197 9822144-2 1998 These 2 studies, the Fosinopril versus Amlodipine Cardiovascular Events Randomized Trial (FACET) and Appropriate Blood Pressure Control in Diabetes (ABCD), showed that angiotensin-converting enzyme (ACE) inhibitors may be preferable to calcium antagonists for managing hypertension in diabetic patients; they do not, however, show any harm attributable to calcium antagonists. Calcium 356-363 angiotensin I converting enzyme Homo sapiens 168-197 9822144-3 1998 Indeed, results of the FACET study suggest that the combination of an ACE inhibitor and a calcium antagonist is effective antihypertensive therapy. Calcium 90-97 angiotensin I converting enzyme Homo sapiens 24-27 9869001-4 1998 VASCULAR EFFECTS OF NEWER ANTIHYPERTENSIVE AGENTS: The newer antihypertensive agents that affect intracellular calcium pathways either directly or indirectly, such as calcium antagonists or angiotensin converting enzyme (ACE) inhibitors, may exert vascular protective effects, partly by regressing vascular remodeling and by correcting endothelial dysfunction. Calcium 111-118 angiotensin I converting enzyme Homo sapiens 190-219 9869001-4 1998 VASCULAR EFFECTS OF NEWER ANTIHYPERTENSIVE AGENTS: The newer antihypertensive agents that affect intracellular calcium pathways either directly or indirectly, such as calcium antagonists or angiotensin converting enzyme (ACE) inhibitors, may exert vascular protective effects, partly by regressing vascular remodeling and by correcting endothelial dysfunction. Calcium 111-118 angiotensin I converting enzyme Homo sapiens 221-224 9231892-4 1997 The results of the study demonstrate that the fixed combination of a calcium antagonist and an angiotensin converting enzyme (ACE) inhibitor allows one to obtain an effective and balanced blood pressure control throughout the 24 h. Calcium 69-76 angiotensin I converting enzyme Homo sapiens 95-124 9493699-7 1997 In this group, typical adverse events of calcium antagonists, such as headache, flushing, ankle edema, or palpitations, were observed only in 5%, 2%, 1%, and 0%, respectively, dry cough, considered typical for ACE inhibitors, was observed in only 1% of the combination group. Calcium 41-48 angiotensin I converting enzyme Homo sapiens 210-213 9855029-6 1998 The Saskatchewan analysis was a rigorous examination of actual practice treatment for hypertension, which demonstrated that angiotensin-converting enzyme inhibitors were associated with the highest 1- and 4.5-year persistence rates and the lowest discontinuation rates among calcium antagonists, beta-blockers and diuretics. Calcium 275-282 angiotensin I converting enzyme Homo sapiens 124-153 9674632-8 1998 These findings suggest that angiotensin-converting enzyme inhibition improves the impaired endothelium-dependent renovascular relaxation in patients with essential hypertension due to the increase in nitric oxide production and that the reduction in blood pressure with a calcium antagonist does not play a major role in the potentiation of L-arginine/nitric oxide-mediated effects. Calcium 272-279 angiotensin I converting enzyme Homo sapiens 28-57 18370550-18 1998 However, it is possible that the concomitant administration of ACE inhibitors could reduce the reflex neurohumoral activity caused by some calcium antagonists, while preserving some of the beneficial properties of these agents. Calcium 139-146 angiotensin I converting enzyme Homo sapiens 63-66 9736438-7 1998 Finally, a protective role for ACE inhibitors has been reported even in diabetic hypertensive patients, in whom such agents can significantly reduce the occurrence of major cardiovascular events (CAD and stroke) with a pattern that is largely independent of blood pressure control and is not observed with the use of calcium antagonists. Calcium 317-324 angiotensin I converting enzyme Homo sapiens 31-34 9324122-11 1997 The combination of a heart rate lowering calcium antagonist, particularly verapamil, with an ACE inhibitor offers some potential to either prevent or reverse target organ disease associated with hypertension and diabetes. Calcium 41-48 angiotensin I converting enzyme Homo sapiens 93-96 9231892-4 1997 The results of the study demonstrate that the fixed combination of a calcium antagonist and an angiotensin converting enzyme (ACE) inhibitor allows one to obtain an effective and balanced blood pressure control throughout the 24 h. Calcium 69-76 angiotensin I converting enzyme Homo sapiens 126-129 9231894-10 1997 As has been noted in the other papers in this supplement, the combination of an ACE inhibitor and a calcium antagonist is particularly attractive, not only to treat hypertension, but also to ameliorate other cardiovascular risk factors. Calcium 100-107 angiotensin I converting enzyme Homo sapiens 80-83 1345261-6 1992 ACE-inhibitors, beta-blockers and calcium antagonists all reduced left ventricular mass (LVM) through a reduction in wall hypertrophy, the effect being most pronounced with ACE-inhibitors. Calcium 34-41 angiotensin I converting enzyme Homo sapiens 173-176 9218196-8 1997 Recent evidence indicates that the combination of a long-acting calcium antagonist and an angiotensin converting enzyme inhibitor is particularly effective in reducing cardiovascular risk. Calcium 64-71 angiotensin I converting enzyme Homo sapiens 90-119 9037321-8 1997 We conclude that the changes in the studied metabolic variables and serum ACE activity during ACE inhibitor treatment are related to alterations in mineral status and the balance between calcium and magnesium concentrations in serum. Calcium 187-194 angiotensin I converting enzyme Homo sapiens 74-77 9037321-8 1997 We conclude that the changes in the studied metabolic variables and serum ACE activity during ACE inhibitor treatment are related to alterations in mineral status and the balance between calcium and magnesium concentrations in serum. Calcium 187-194 angiotensin I converting enzyme Homo sapiens 94-97 8948517-8 1996 Based on such considerations, recent randomized prospective studies have been initiated to compare the renal protective effects of combination calcium antagonist-ACE inhibitor therapy versus monotherapy with agents of either of these two antihypertensive classes. Calcium 143-150 angiotensin I converting enzyme Homo sapiens 162-165 8769047-6 1996 Angiotensin converting enzyme (ACE) inhibitors that were unavailable in 1982, were the most commonly prescribed antihypertensive at 35.8% in 1993-4 and calcium antagonists increased from 2% in 1982 to 22.1% in 1993-4. Calcium 152-159 angiotensin I converting enzyme Homo sapiens 0-29 8602055-8 1996 FINDINGS: Compared with beta-blockers (4819 person-years, 65 events), after adjustment for confounders the relative risk for GIH associated with ACE inhibitor (772 person-years, 13 events) was 1.23 (95% CI 0.66-2.28) and with calcium antagonists (1510 person-years, 42 events) it was 1.86 (1.22-2.82). Calcium 226-233 angiotensin I converting enzyme Homo sapiens 145-148 7594429-10 1995 CONCLUSIONS: The combination of alpha-blockade and calcium antagonism has not previously been studied and should be useful for resistant hypertensives who have not tolerated beta-blockade or ACE inhibitors. Calcium 51-58 angiotensin I converting enzyme Homo sapiens 191-194 8177486-0 1994 Prevention of anaphylactoid reactions to high-flux membrane dialysis and ACE inhibitors by calcium. Calcium 91-98 angiotensin I converting enzyme Homo sapiens 73-76 8200012-2 1993 The aim of this study was to assess the aortic distensibility in a group of 10 patients with essential hypertension in comparison with a control group, with regard to the vascular effects of a long-term anti-hypertensive treatment with calcium-antagonists and ACE-inhibitors. Calcium 236-243 angiotensin I converting enzyme Homo sapiens 260-263 2261144-7 1990 Since the primary action of ACE inhibitors is to block the renin system, a dramatic response to monotherapy suggests a large renin factor while the lack of a response suggests a low-renin state more amenable to treatment with a diuretic or calcium antagonist. Calcium 240-247 angiotensin I converting enzyme Homo sapiens 28-31 1663586-0 1991 Endothelium-derived bradykinin is responsible for the increase in calcium produced by angiotensin-converting enzyme inhibitors in human endothelial cells. Calcium 66-73 angiotensin I converting enzyme Homo sapiens 86-115 1663586-1 1991 The effects of angiotensin-converting enzyme (ACE) inhibitors on intracellular calcium concentration ([Ca2+]i) were examined under resting conditions and after stimulation with bradykinin in cultured human umbilical vein endothelial cells. Calcium 79-86 angiotensin I converting enzyme Homo sapiens 46-49 1720478-8 1991 The results indicate that combined treatment with a calcium antagonist and an angiotensin-converting enzyme (ACE) inhibitor is effective in lowering blood pressure, and is well tolerated as long-term therapy. Calcium 52-59 angiotensin I converting enzyme Homo sapiens 109-112 2096214-6 1990 Combination therapy with calcium antagonist + diuretic was associated with a 13.4 +/- 1.7/5.4 +/- 0.9 mmHg drop in supine BP; the ACE inhibitor + diuretic combination lowered supine BP by 12.3 +/- 1.6/8.0 +/- 0.9 mmHg compared with monotherapy (all P less than 0.001 by paired t-test). Calcium 25-32 angiotensin I converting enzyme Homo sapiens 130-133 2526703-9 1989 b) In animals some factors (high-calcium diet, calcium blockers, ACE inhibitors) are able to reduce aminoglycoside nephrotoxicity; some of them are operating through inhibition of uptake. Calcium 33-40 angiotensin I converting enzyme Homo sapiens 65-68 2649357-14 1989 Alternatively, calcium antagonists of the verapamil type and ACE inhibitors can be employed. Calcium 15-22 angiotensin I converting enzyme Homo sapiens 61-64 2490816-2 1989 The angiotensin converting enzyme (ACE)-inhibiting agents have emerged with the diuretic agents, beta-adrenergic receptor-blocking agents, and calcium antagonists as therapeutic options for major consideration during the initial treatment of hypertensive patients. Calcium 143-150 angiotensin I converting enzyme Homo sapiens 4-33 2490816-2 1989 The angiotensin converting enzyme (ACE)-inhibiting agents have emerged with the diuretic agents, beta-adrenergic receptor-blocking agents, and calcium antagonists as therapeutic options for major consideration during the initial treatment of hypertensive patients. Calcium 143-150 angiotensin I converting enzyme Homo sapiens 35-38 33349633-4 2020 Here, we report that calcium channel blockers (CCBs), a type of antihypertensive drug that is widely used in clinics, inhibited the post-entry replication events of SARS-CoV-2 in vitro, while no in vitro anti-SARS-CoV-2 effect was observed for the two other major types of antihypertensive drugs, namely, angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers. Calcium 21-28 angiotensin I converting enzyme Homo sapiens 305-334 3054277-1 1988 Angiotensin converting enzyme (ACE)-inhibitors combined with diuretics and, if necessary, with calcium antagonists can be used with good success for the treatment of otherwise resistant hypertension. Calcium 95-102 angiotensin I converting enzyme Homo sapiens 0-29 2450244-1 1987 Recent observations suggest that calcium antagonists may enhance the antihypertensive effects of angiotensin-converting enzyme (ACE) inhibitors. Calcium 33-40 angiotensin I converting enzyme Homo sapiens 97-126 2450244-1 1987 Recent observations suggest that calcium antagonists may enhance the antihypertensive effects of angiotensin-converting enzyme (ACE) inhibitors. Calcium 33-40 angiotensin I converting enzyme Homo sapiens 128-131 6258828-3 1981 When assayed with the method described, ACE is optimally active at pH 8 with a calcium concentration exceeding 0.75 mmol/l urine, and is chloride independent. Calcium 79-86 angiotensin I converting enzyme Homo sapiens 40-43 3583208-15 1987 Alternatively, calcium antagonists of the verapamil-type or ACE-inhibitors may be used. Calcium 15-22 angiotensin I converting enzyme Homo sapiens 60-63 3033183-3 1986 On the basis of studies demonstrating cellular membrane and calcium homoeostatic derangements, and an age-dependent transition of overall cardiovascular regulation and peripheral vasoconstrictor forces during the course of essential hypertension, an alternative treatment concept is proposed: angiotensin converting enzyme inhibitors or beta-blockers can primarily be used in younger patients and those with a high renin, while calcium antagonists are used in place of diuretics in older, low-renin or black patients. Calcium 428-435 angiotensin I converting enzyme Homo sapiens 293-322 33813847-7 2021 In veterans without chronic kidney disease, ACE inhibitor/ARBs were associated with a lower risk of incident heart failure compared with all other classes (hazard ratio [95% CI]: beta-blockers, 1.52 [1.11-2.09]; calcium channel blockers 1.48 [1.00-2.19]; diuretics 1.52 [1.07-2.16]). Calcium 212-219 angiotensin I converting enzyme Homo sapiens 44-47 33216879-8 2021 CONCLUSIONS: Combination therapy adding a calcium channel blocker, rather than hydrochlorothiazide, to an angiotensin converting enzyme inhibitor was more effective in preventing composite cardiovascular events even in hypertensive patients achieving aggressive systolic blood pressure targets as well as in those with apparent resistant hypertension. Calcium 42-49 angiotensin I converting enzyme Homo sapiens 106-135 34001757-8 2021 In men with dyslipidemia, use of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker with diuretics and in women, only calcium channel blockers showed higher for BP control. Calcium 139-146 angiotensin I converting enzyme Homo sapiens 33-62 33954871-9 2021 Consistent distress was more prevalent in women (22% vs 15%, p = 0.004) and was related to the use of more angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and diuretics in women and to calcium antagonist use as well as lower adherence levels in men. Calcium 208-215 angiotensin I converting enzyme Homo sapiens 107-136 32931573-9 2020 Glaucoma was more common among hypertensives (OR, 1.25; 95% CI, 1.16-1.35; P < 0.001); among those using angiotensin-converting enzyme (ACE) inhibitors (OR, 1.35; 95% CI, 1.18-1.55; P < 0.001); and among those using calcium-channel blockers (OR, 1.19; 95% CI, 1.01-1.40; P = 0.039). Calcium 216-223 angiotensin I converting enzyme Homo sapiens 105-134 32931573-9 2020 Glaucoma was more common among hypertensives (OR, 1.25; 95% CI, 1.16-1.35; P < 0.001); among those using angiotensin-converting enzyme (ACE) inhibitors (OR, 1.35; 95% CI, 1.18-1.55; P < 0.001); and among those using calcium-channel blockers (OR, 1.19; 95% CI, 1.01-1.40; P = 0.039). Calcium 216-223 angiotensin I converting enzyme Homo sapiens 136-139 30821177-11 2020 Further analysis showed a dose-response relationship for all drugs except ACE-inhibitors and calcium channel blockers. Calcium 93-100 angiotensin I converting enzyme Homo sapiens 74-77 32550191-2 2020 The aim of this study was to evaluate which combination therapy, calcium channel blocker (CCB) with angiotensin converting enzyme inhibitor (ACEI) or CCB with angiotensin II type 1 receptor blocker (ARB), is best in reducing/preventing the development of NODM during 4-year follow-up periods in non-diabetic hypertensive Korean patients. Calcium 65-72 angiotensin I converting enzyme Homo sapiens 100-129 32395481-1 2020 Background: Our previous studies have found that single nucleotide polymorphisms (SNPs) of tribbles homolog 3 (TRIB3) are related to the hypotensive effects of calcium-channel blockers (CCBs) and angiotensin-converting enzyme (ACE) inhibitors. Calcium 160-167 angiotensin I converting enzyme Homo sapiens 196-225 32395481-1 2020 Background: Our previous studies have found that single nucleotide polymorphisms (SNPs) of tribbles homolog 3 (TRIB3) are related to the hypotensive effects of calcium-channel blockers (CCBs) and angiotensin-converting enzyme (ACE) inhibitors. Calcium 160-167 angiotensin I converting enzyme Homo sapiens 227-230 25102744-14 2014 Replacing the previous therapy different ACE inhibitors, sartans and calcium antagonists to the fixed combination amlodipine and lisinopril) (drug EKVATOR), leads to a rapid, pronounced, and safe reduction of BP and improve health in the majority of patients with previously uncorrected BP. Calcium 69-76 angiotensin I converting enzyme Homo sapiens 41-44 31965780-3 2019 Moreover, studies such as ASCOT and ACCOMPLISH demonstrate a superiority of the ACE-inhibitor/calcium antagonist association over beta-blocker/diuretic associations and especially towards the ACE-inhibitor/diuretic combination, whereas there is no scientific evidence of efficacy with respect to cardiovascular events on the part of AT-1 antagonist/calcium antagonist combinations. Calcium 94-101 angiotensin I converting enzyme Homo sapiens 80-83 26197790-6 2015 After logistic regression analysis, diabetic nephropathy, doxazosin use, ACE inhibitor use and lower hemoglobin were associated with calcium antagonist use. Calcium 133-140 angiotensin I converting enzyme Homo sapiens 73-76 25485720-12 2015 Nonetheless, significant reductions of stroke, major cardiovascular events, cardiovascular and all-cause death were obtained with calcium antagonists (10 RCTs, 30, 359 patients); stroke, coronary heart disease, heart failure and major cardiovascular events by ACE inhibitors (12 RCTs, 35, 707 patients); and stroke, heart failure and major cardiovascular events by ARBs (13 RCTs, 65, 256 patients). Calcium 130-137 angiotensin I converting enzyme Homo sapiens 260-263